Skip to Main Content

Author Details

Toni M Brand
University of Wisconsin School of Medicine and Public Health
2011
35
23
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36052495Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2022
36052496Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2022
34261774Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV<sup>+</sup> Patients.Clin Cancer Res2021
34752142Retraction.Sci Signal2021
30442378Corrigendum to: "Nuclear EGFR as a molecular target in cancer" [Radiother Oncol 108 (2013) 370-77].Radiother Oncol2019
30936412Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer.Mol Cancer Ther2019
30683736Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer.J Exp Med2019
30518873Correction: Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.Oncogene2019
30390071Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation.Oncogene2019
29792310BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.Cancer Res2018
30209081Multiple Routes to Oncogenesis Are Promoted by the Human Papillomavirus-Host Protein Network.Cancer Discov2018
30510088Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.Clin Cancer Res2018
29440171Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2018
28049763RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.Sci Signal2017
27986750Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV<sup>+</sup> Patients.Clin Cancer Res2017
26808665Adaptive responses to antibody based therapy.Semin Cell Dev Biol2016
27422810Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.Mol Cancer Ther2016
25767293AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.Clin Cancer Res2015
24327519Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.Mol Cancer Ther2014
25344208Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.Mol Cancer2014
25136066AXL mediates resistance to cetuximab therapy.Cancer Res2014
24634415Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.Mol Cancer Ther2014
22430206Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.Oncogene2013
24204198Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.Neoplasia2013
23830194Nuclear EGFR as a molecular target in cancer.Radiother Oncol2013
23998444Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.Discov Med2013
23951180Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3.PLoS One2013
23628526Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.Lung Cancer2013
23792636Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer.Cancer Biol Ther2013
23760490Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab.Cancer Biol Ther2013
22714415KRAS mutant colorectal tumors: past and present.Small GTPases2012
21228636Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate.Cancer Biol Ther2011
21293176Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.Cancer Biol Ther2011
21725209Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.Cancer Biol Ther2011
22127113The nuclear epidermal growth factor receptor signaling network and its role in cancer.Discov Med2011
  • 1 - 35 of 35

Recommended Authors

Shilpa Bhatia
University of Colorado Denver at Anschutz Medical Campus
Career Start Year 2011
Number of shared co-authors 0
Yisong Wang
Lombardi Comprehensive Cancer Center, Georgetown University
Career Start Year 2010
Number of shared co-authors 0
Luping Lin
Incyte Research Institute, Incyte Corporation
Career Start Year 2010
Number of shared co-authors 5
Katherine R Singleton
Duke University
Career Start Year 2009
Number of shared co-authors 0
Alan L Ho
Memorial Sloan Kettering Cancer Center
Career Start Year 2009
Number of shared co-authors 2
Stephen B Keysar
University of Colorado Denver
Career Start Year 2006
Number of shared co-authors 11
Gabi Tarcic
Hadassah Ein-Kerem Medical Center Campus
Career Start Year 2004
Number of shared co-authors 9
Jalna Meens
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 0
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 0
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
Ezra E W Cohen
university of california san diego Health System
Career Start Year 2001
Number of shared co-authors 8
Hyunseok Kang
Johns Hopkins University
Career Start Year 2000
Number of shared co-authors 10
Benjamin Solomon
Peter MacCallum Cancer Centre
Career Start Year 2000
Number of shared co-authors 0
Andrea Bertotti
Candiolo Cancer Institute - FPO IRCCS
Career Start Year 2000
Number of shared co-authors 0
Christopher D Willey
University of Alabama at Birmingham
Career Start Year 2000
Number of shared co-authors 1
David Neil Hayes
Center for Cancer Research, University of Tennessee Health Science Center
Career Start Year 1999
Number of shared co-authors 7
Eddy S Yang
University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center
Career Start Year 1999
Number of shared co-authors 0
Collin M Blakely
University of California san francisco
Career Start Year 1998
Number of shared co-authors 5
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 9
Mark M Moasser
Helen Diller Family Comprehensive Cancer Center
Career Start Year 1994
Number of shared co-authors 3
Livio Trusolino
Candiolo Cancer Institute - FPO IRCCS
Career Start Year 1993
Number of shared co-authors 0
Ron Bose
Washington University School of Medicine
Career Start Year 1991
Number of shared co-authors 2
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 4
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 1
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 1
Jeffrey N Myers
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 7
Pasi A J??nne
Dana-Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 2
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 13
Dennis J Slamon
David Geffen School of Medicine at university of california los angeles
Career Start Year 1973
Number of shared co-authors 1
Ming-Sound Tsao
University Health Network, University of Toronto
Career Start Year 1972
Number of shared co-authors 0

Collaborators

Jennifer R Grandis
University of California san francisco
Co-authored papers 9
Neil E Bhola
Zai Lab (US) LLC
Co-authored papers 7
Yan Zeng
Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College
Co-authored papers 7
Daniel E Johnson
University of California San Francisco
Co-authored papers 6
Umamaheswar Duvvuri
University of Pittsburgh School of Medicine
Co-authored papers 6
Theresa M LaVallee
Parker Institute for Cancer Immunotherapy
Co-authored papers 5
Stefan Hartmann
University Hospital Wurzburg
Co-authored papers 5
Hua Li
University of California san francisco
Co-authored papers 5
Max V Ranall
University of California San Francisco
Co-authored papers 5
Sourav Bandyopadhyay
University of California San Francisco
Co-authored papers 5
Nevan J Krogan (CM4AI)
University of California San Francisco
Co-authored papers 4
Rachel A O'Keefe
University of California San Francisco
Co-authored papers 4
Julie E Bauman
George Washington University
Co-authored papers 4
Michelle A Ozbun
The University of New Mexico School of Medicine
Co-authored papers 3
Margaret Soucheray
J. David Gladstone Institutes
Co-authored papers 3
Carolyn Kemp
University of Pittsburgh Medical Center, Eye and Ear Institute
Co-authored papers 3
Mark W Lingen
University of Chicago Pritzker School of Medicine
Co-authored papers 2
Kathleen E Franks-Skiba
University of California, USA Quantitative Biosciences Institute (QBI) san francisco
Co-authored papers 1
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 1
Rifat Hasina
University of Chicago Medicine
Co-authored papers 1
Albert J van der Kogel
University of Wisconsin School of Medicine and Public Health
Co-authored papers 1
Jeffrey R Johnson
Gladstone Institutes
Co-authored papers 1
Scott R VandenBerg
University of California san francisco
Co-authored papers 1
Jason F Kreisberg
University of California San Diego
Co-authored papers 1
Victor Olivas
University of California san francisco
Co-authored papers 1
Jacques Archambault
McGill University
Co-authored papers 1
Lin Wang
Co-authored papers 1
Mi-Ok Kim
University of California san francisco
Co-authored papers 1
Tasha Johnson
Quantitative Biosciences Institute (QBI), University of California san francisco
Co-authored papers 1
Priya S Shah
University of California davis
Co-authored papers 1
Release 1.2